این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Basic Medical Sciences، جلد ۲۸، شماره ۱۲، صفحات ۱۷۱۵-۱۷۲۴
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Comparison of the therapeutic effects of sacubitril and valsartan combination versus metformin in experimentally induced polycystic ovary syndrome in rats
چکیده انگلیسی مقاله Objective(s): Our study aimed to demonstrate the therapeutic effects of sacubitril (an inhibitor of neprilysin) and/or valsartan (an ARB) in an experimentally induced polycystic ovary syndrome (PCOS) model and in PCOS-induced insulin resistance.Materials and Methods: After 21 days of letrozole 1 mg/kg administration, rats were confirmed to have PCOS by the vaginal smear method. Following PCOS induction, the experiment was terminated after 15 days of drug treatment. Metformin 300 mg/kg, sacubitril 30 mg/kg, and valsartan 31 mg/kg were administered orally every 15 days. Fasting insulin levels and oral glucose tolerance test (OGTT) were performed to measure insulin resistance and calculate homeostatic model assessment - insulin resistance (HOMA-IR). At the end of the experiment, biochemical analyses were performed on blood samples, and histological studies were conducted on tissue samples.Results: The sacubitril and valsartan combination significantly improved impaired glucose tolerance and HOMA-IR. Serum neprilysin (NEP) levels were found to be significantly higher in the PCOS group than in the healthy group, while atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) levels were found to be significantly lower. The sacubitril+valsartan combination provided the greatest improvement in PCOS-related changes in serum NEP, ANP, BNP, angiotensin II (ANGII), hormone, and lipid levels. The application of sacubitril+valsartan provided an important treatment for insulin resistance due to PCOS by increasing the expression of insulin resistance (IR), insulin receptor substrate 1 (IRS-1), and insulin receptor substrate 2 (IRS-2).Conclusion: Sacubitril and valsartan combination has been shown to have significant therapeutic benefits for PCOS. It markedly reduces cystic follicles and PCOS-associated insulin resistance, improves serum lipid levels, and is supported by pathological findings. 
کلیدواژه‌های انگلیسی مقاله insulin resistance, Neprilysin and ARB, PCOS, Rat, Sacubitril and Valsartan
نویسندگان مقاله | Muhammed Yayla
Department of Pharmacology, Faculty of Medicine, Selcuk University, 42100, Konya/Turkey


| Bengul Ozdemir Sarikaya
Department of Histology and Embryology, Faculty of Medicine, Kafkas University, 36100, Kars/Turkey


| Erdem Toktay
Department of Histology and Embryology, Faculty of Medicine, Kafkas University, 36100, Kars/Turkey


| Huseyin Gul
Department of Medical Biochemistry, Faculty of Medicine, Kafkas University, 36100, Kars/Turkey


| Ugur Ermis
Department of Pharmacology, Faculty of Medicine, Kafkas University, 36100, Kars/Turkey


| Damla Binnetoglu
Department of Pharmacology, Faculty of Medicine, Kafkas University, 36100, Kars/Turkey
نشانی اینترنتی https://ijbms.mums.ac.ir/article_26801.html
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات